The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Mon, 09th Dec 2019 11:23

(Alliance News) - Open Orphan PLC and hVIVO PLC on Monday said they have agreed terms on a reverse takeover, which would value the latter at GBP13.0 million.

Under the terms of the agreement, hVIVO shareholders will receive 2.47 new Open Orphan shares per hVIVO share. The deal values hVIVO shares at 15.56 pence each, a 34% premium to the clinical development services company's closing price of 11.62p on Friday.

hVIVO shares were trading 3.2% higher at 12.00p each in London on Monday morning. Drug consulting firm Open Orphan, also listed in London, was 13% lower at 5.00p each.

As the tie-up is deemed a reverse acquisition, Open Orphan needs the approval of its shareholders at a January 6 general meeting to confirm the deal.

Open Orphan said it expects to issue 205.5 million shares under the terms of the merger, with hVIVO shareholders owning just shy of 45% of the enlarged firm.

Open Orphan said: "Open Orphan and hVIVO are AIM-quoted groups that share a similar vision for the future of European Clinical Research Organisations and an entrepreneurial approach to developing further their business through a focus on operational efficiency, organic growth and targeted acquisitions to expand their geographic and service capabilities.

"The Open Orphan directors and the hVIVO directors believe that the combination of the businesses will result in synergies across the enlarged group with each business providing complementary services with limited overlap in existing capabilities and customers."

hVIVO's directors, which have backed the offer, hold a 0.3% stake in the company. Open Orphan shareholders, with an interest totalling roughly 30% of the firm, have also supported the tie-up.

Open Orphan Chief Executive Cathal Friel said: "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins.

"The merger allows the combined business to maximise shareholder value through delivering cost and revenue synergies across the businesses and one that is better positioned to consistently capture greater market share as part of a properly profitable business with losses confined to the past."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
14 Feb 2022 12:22

Open Orphan launches project collecting viral strains from ill employees

(Sharecast News) - Contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO had launched the 'STRiVE' project, to collect respiratory viral strains suitable for challenge agents from consenting hVIVO employees.

Read more
2 Feb 2022 19:37

TRADING UPDATES: Portfolio updates from Scirocco, Tekcapital, MetalNRG

TRADING UPDATES: Portfolio updates from Scirocco, Tekcapital, MetalNRG

Read more
2 Feb 2022 13:03

Open Orphan reports on world's first Covid-19 characterisation study

(Sharecast News) - Specialist contract research organisation (CRO) Open Orphan announced the results from the world's first Covid-19 characterisation study, which was a partnership between its hVIVO subsidiary, Imperial College London, the Vaccine Taskforce, the Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust.

Read more
20 Jan 2022 21:13

TRADING UPDATES: GSTechnologies buys crypto exchange; Altus realigns

TRADING UPDATES: GSTechnologies buys crypto exchange; Altus realigns

Read more
21 Dec 2021 15:48

Open Orphan signs £5m human flu study contract

(Sharecast News) - Contract research organisation Open Orphan announced on Tuesday that its subsidiary hVIVO has signed a £5m influenza human challenge study contract with an unnamed biotechnology company, developing an antiviral drug for protection against respiratory viral infections.

Read more
21 Dec 2021 12:23

IN BRIEF: Open Orphan's subsidiary signs GBP5 million contract

IN BRIEF: Open Orphan's subsidiary signs GBP5 million contract

Read more
10 Dec 2021 11:32

Open Orphan signs contract to test antiviral candidate

(Sharecast News) - Specialist contract research organisation Open Orphan announced on Friday that its subsidiary hVIVO has signed a $13.4m contract with an unnamed US-based biotechnology company to test its novel antiviral candidate, using the 'hVIVO Influenza Human Challenge' study model.

Read more
10 Dec 2021 11:28

AIM WINNERS & LOSERS: Omega sinks on UK government repayment demand

AIM WINNERS & LOSERS: Omega sinks on UK government repayment demand

Read more
10 Dec 2021 11:12

Open Orphan shares surge 12% on GBP13 million contract win

Open Orphan shares surge 12% on GBP13 million contract win

Read more
6 Dec 2021 21:32

TRADING UPDATES: Katoro's Blyvoor IPO on hold; Spectra bags new orders

TRADING UPDATES: Katoro's Blyvoor IPO on hold; Spectra bags new orders

Read more
29 Nov 2021 14:33

EXECUTIVE CHANGES: SIMEC and Feedback tap new chief financial officers

EXECUTIVE CHANGES: SIMEC and Feedback tap new chief financial officers

Read more
19 Nov 2021 12:20

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

Read more
17 Nov 2021 12:09

TRADING UPDATES: Wincanton Primark deal; Mode Global cuts bitcoin fees

TRADING UPDATES: Wincanton Primark deal; Mode Global cuts bitcoin fees

Read more
17 Nov 2021 10:50

Open Orphan subsidiary locks in £5.1m contract with biopharma firm

(Sharecast News) - Contract research organisation Open Orphan revealed on Wednesday that its hVIVO subsidiary had signed a £5.1m contract with a biopharmaceutical company to test its investigational medicinal product.

Read more
15 Nov 2021 12:19

TRADING UPDATES: Billington project delays; Urban Logistics cash raise

TRADING UPDATES: Billington project delays; Urban Logistics cash raise

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.